The myocardial infarction
therapeutics pipeline is expected to increase in future due to rise in
prevalence of myocardial infarction. Myocardial infarction is also commonly
known as heart attack which is symptomatized by decrease in blood supply to the
heart muscle due to coronary artery disease. According to American Heart Association,
the mortality rate due to cardiovascular disease is higher than other disease. According
to British Heart Foundation, in 2015, around 150,155 deaths, occurred due to cardiovascular
disease in the U.K. Some of the drivers for the growth of the myocardial
infarction therapeutics pipeline include increasing incidence of coronary
artery disease, change in lifestyle, lack of exercise, increase in incidence of
blood pressure and obesity. According to World Health Organization (WHO), there
has been an increase in incidence of heart disease in smokers as compared to
non-smokers.
Explore Report at: https://www.psmarketresearch.com/market-analysis/myocardial-infarction-therapeutics-pipeline-analysis
The myocardial infarction is
a state of blockage of flow of oxygen-rich blood to a section of heart muscle,
leading to the death of muscle. Myocardial infarction most often occurs in case
of coronary artery disease in which a waxy substance, known as plaque gets
build up inside the coronary artery, decreasing the oxygen-rich blood supply to
the heart. This condition is also known as atherosclerosis due to which area of
plaque break open inside a coronary artery, leading to the formation of clot.
This clot gets bigger with time and leads to the blockage of coronary artery.
The heart failure is a condition in which heart cannot pump enough blood to
meet the body need. In various cases, a discomfort occurs in the center or left
side of the chest which can last for few minutes which goes away and comes
back. The upper body discomfort and shortness of breath also occurs in case of
cardiac disorders.
Some of the key players having a pipeline of myocardial infarction therapeutics include Pfizer Inc., Novartis N.V., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, AstraZeneca, Apotex Inc., Par Pharmaceutical Companies, Inc., Sandoz, Mylan N.V.
No comments:
Post a Comment